- Home
- YMM vs JAZZ Comparison
YMM vs JAZZ Comparison
Compare YMM & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMM | JAZZ |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 10.4B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | YMM | JAZZ |
|---|---|---|
| Price | $9.96 | $170.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | $12.00 | ★ $207.19 |
| AVG Volume (30 Days) | ★ 11.1M | 1.1M |
| Earning Date | 03-04-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.93% | N/A |
| EPS Growth | ★ 29.34 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | $1,751,813,549.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $11.40 | $6.00 |
| Revenue Next Year | $7.83 | $6.35 |
| P/E Ratio | $18.99 | ★ N/A |
| Revenue Growth | ★ 19.09 | 4.14 |
| 52 Week Low | $9.45 | $95.49 |
| 52 Week High | $14.07 | $182.99 |
Technical Indicators
Market Signals| Indicator | YMM | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 55.75 |
| Support Level | $9.76 | $165.01 |
| Resistance Level | $10.24 | $172.59 |
| Average True Range (ATR) | 0.45 | 6.13 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 17.07 | 74.54 |
Price Performance
Historical ComparisonAbout YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.